Arena Pharmaceuticals, Inc. (ARNA)

[gixxer11]

You forget @ where most people hold positions well under 2 and mostly mid 2"s maybe some 3"s


Lmao - still a hell a profit @ 4


GLTY

[AntiMarketMaker]

5cap it is not too late. Call your broker and see if you can borrow shares to short. The value of the PO might be at $4. Good luck, because I am trying to get more shares to borrow increase my position. Who ever got short position above 7.5 will be rich.

[AntiMarketMaker]

So many people now have short position I can't find any brokage to loan me some shares pending the value of the public offering. MAN a whole lot of money will be made by shorters who have short position above 7.50.

[AntiMarketMaker]

IMO

If you want to make money off ARNA, do not buy yet. Wait for the value of the offering. Do not buy until the NAKED SHORTERS short ARNA down passed the public offering amount than buy.

[AntiMarketMaker]

WEEEEEEEEE I told you ARNA was going to pull a DSCO on your behind WEEEEEEEEEEEEEEEEEEEEEEEEEEE

[5cap]

Totally agree. Notice that no details are available, only the fact that they are working on it. So the IB plan could easily be an offering at $7 when the stock is at $8. I don't believe anyone is going to be able to buy millions of shares at $3, as the post I responded to was sort of implying. This has the feel that the company realized that some people knew about this financing and they thought they should get the word out.

[The_Bull]

This sure puts a little damper on things......

I still believe it will be approved....

Now at what price......?

[linhdtu]

In my experience, the offering price of a secondary is usually and almost always set at a discount to the current mkt price. The degree of discount is set (or advised to the company) by the leading investment banker(s) hired for the job. It is the job of the IBs to figure out how much they can sell for, meaning what kind of a price the mkt can/will support and that also depends on how many shares the company wish to sell.

[stockhero]

For the people who missed the 6's...now may be the time to make up for it. Once this is approved on June 27th, this will be the biggest thing out there.

[gixxer11]

Your numbers and knowledge mean absolute squat to me !!

GLTY

[BIDWACKIE]

Sounds like IF they need to and not that they did. I could be wrong though.

<SAN DIEGO, May 15, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering>

[5cap]

nonsense, they are trying to raise money so they aren't going to sell shares at $3 if they could get more. When the smoke clears you'll see a placement at something like $7 or $8.

[gratitude]

Sorry for the longs here. I tried to warn them and they didn't listen. O/s is 180 mills and arna wants to raise a/s from 250 mills to about 375 million i believe, which means from $6 it could go down to $4. Now having in mind the average price was $2 before it ramped up for approval, i won't be surprised to see a $3 along the way. Sorry guys, that's how we all learn!

[ProfitScout]

We will see what happens from here but ARNA investors have made some really great profits recently. I hope everyone locked in at least some gains with sell or stop orders.

[BIDWACKIE]

NO wonder this dropped the way it did today.

[BIDWACKIE]

What's this going to open at tomorrow? Below $5.00 ???

[~MulaGreen~]

Good short still,Heading back to 3 level,jmhtto

[~MulaGreen~]

Last Trade 5.62 AH while typing...!!!

[ProfitScout]

Arena Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO, May 15, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Jefferies & Company, Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. BMO Capital Markets is acting as a co-manager for the offering.

A registration statement relating to the shares described above was previously filed with and has become effective by rule of the Securities and Exchange Commission (SEC). A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained from Jefferies & Company, Inc., Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th floor, New York, NY 10022 or by telephone at 877-547-6340 or by email at [e-mail], or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402 or by telephone at 800-747-3924 or by email at [e-mail].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's expectations with respect to its proposed offering and Arena's focus, research and development programs, and ability to discover and develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering; the timing of regulatory review is uncertain and Arena's applications for regulatory approval of lorcaserin may not be reviewed when or as anticipated; the timing, results, influence and other impact of FDA advisory committee meetings relating to lorcaserin and other drug candidates; the FDA may not complete its review of the lorcaserin NDA resubmission by the PDUFA date; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena's other research and development programs may not meet safety, efficacy or other regulatory requirements or otherwise be sufficient for regulatory review or approval; even if any of Arena's drug candidates is approved for marketing, such approval may be subject to limitations on the indicated uses, restricted distribution methods and other limitations; risks related to commercializing new products; unexpected or unfavorable new data; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and its Current Report on Form 8-K filed with the SEC on May 15, 2012. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Arena Pharmaceuticals, Inc.

Robert E. Hoffman, Vice President, Finance and Chief Financial Officer

858.453.7200



Investor Contact: Russo Partners, LLC
Media Contact: Russo Partners, LLC

Cindy McGee, Vice President
David Schull, President

[e-mail]
[e-mail]

619.213.6995
858.717.2310

[gixxer11]

Are you sure ???

[~MulaGreen~]

Falling Down AH ,Company d i l u t i n g !!!!jmhtto

[lovethatgreen]

http://finance.yahoo.com/news/arena-pharmaceuticals-announces-proposed-public-200100078.html

[OldBen]

I'm going with $4.90 by Friday and I have not seen 100% proof that the last reported 44 million short interest is not hedged in part or whole by long positions. If we get a short squeeze great, but, I would not ignore the charts in the meantime.

[The_Bull]

Read and add your own two cents worth ?????

http://www.eisai.com/news/news201224.html

[vinnybotz]

i picked up a bunch of july $12 calls yesterday @.15. I believe fda approval would be met and stock can easily double by then. I did not want to see how my calls were doing today being the stock is down 9%. I was very surprised when I looked and noticed all the july $10 and up calls were all green. Mine are actually up 25% which is shocking on a day like this. The volume is quite impressive as well. If this doesnt tell you about approval confidence, then I dont know what does. GL to all!

[BIDWACKIE]

Thanks

[~MulaGreen~]

Trading this stock is OT?lollzzzz

[clawmann]

Nevertheless, posts about you specific trades are OT.

[clawmann]

Not until AH on Friday. The shorts are the call writers. They want a close below 6 on Friday.

[~MulaGreen~]

I trade the stock not the Company!Good Luck ::)))

[stockhero]

The short sellers have to pay it off by Friday. There should be a huge squeeze by that day.

[clawmann]

I think posts about one's particular trades are completely OT.
We are here to discus ARNA, not an individual's trades. For an old man, you sure post like a 12-year old.

[~MulaGreen~]

Closing SP now @ 6.05 Happy atm to all ::)))

[BIDWACKIE]

I would hope it's starts heading north next week and we get some momo and close somehere in the $7.00 range at the end of next week.

[clawmann]

I'm calling Friday's close at $5.90. Not because of anything having to do with the company or lorcaserin. Opex week is always manipulator's week. Should be a very nice rebound next week.

They will have a ton of shorts to cover beginning at 4 pm this Friday. Watch for the same game Opex week in June, which ends on Friday the 16th.

[BIDWACKIE]

Clawmann, for most part it's been staying between the $6.21 / $6.22 range. Wow you're good!

<The wall is at $6.20>

[clawmann]

90% certain that will get filled by Friday at the latest.
The call writers want to ensure the May $6.00 calls end out of the money. The wall is at $6.20. That's where they want to hold it so they can tank it on Friday to below $6.00. I have seen this pattern before. Monday should be a nice up day.

[~MulaGreen~]

My SP last Friday won here today folks!!!+($)

[The_Bull]

Put a buy in at 5.98......

[clawmann]

THIS IS OPEX WEEK. THE CALL WRITERS ARE HEAVILY EXPOSED AND ARE SHORTING IT TO TAKE DOWN THE PRICE. They will take their foot of the short pedal on Monday morning and they will start covering. Take advantage. Welcome to opex week shenanigans.
(This also has the earmarks of a bear raid to run stops -there were probably a bunch at $6.00 - the raid was almost certainly initiated by the call writers, as they need shares to cover the calls they wrote).

[7kidsmom]

Just bought a bunch more at 6.. time to move on up ARNA!

[7kidsmom]

Just bought a bunch more at 6.. time to move on up ARNA!

[lovethatgreen]

after yesterdays churn this is no surprise
..


but hardly catastrophic..

the stock needs to find a new trading band..6s are going to be the high end IMO over the next few weeks

[oregon 1]

This just people selling after making their profit. Then they just buy in after this drops to their next buy.and they do it over again.

[BIDWACKIE]

MMs really taking this down.

[penniepincher]

Even though you know it's coming with that many shorts out there....you never quite get to used to it lol :)

[BIDWACKIE]

I think I need some Pepto Bismal for today, not an easy day to stomach! LOL!

[gixxer11]

MM manipulation at its finest - IMO

[7kidsmom]

I keep thinking I should set one.. but at what price with these swings? ARNA could end up very big--with a few dips on the way, and I don't want to miss out! Maybe I should just stop/loss at a high percent... Any ideas for this old gal with her first FDA Stock?

[BIDWACKIE]

It certainly is looking that way.